Contributing To Human Progress : Open Innovation For Infectious Diseases.

Organized By


Monday, November 16th 12:30 - 13:30 (Swiss time)


At Merck, we work to achieve progress for people, communities and society. We use our knowledge and innovation to address healthcare challenges that affect millions of people around the world.

With this in mind, Merck has been engaging to open innovation for global health by collaborating with partners, mainly non-profit organizations and academia in both developed and developing countries.

At Merck, the Global Health team drives these collaborative efforts in line with its mission to improve the health of underserved populations in low- and middle-income countries through our science & technology innovation and our close collaborations with partners.

These ‘open innovation’ partnerships are intended to accelerate research and development for new treatments for infectious diseases, with focus on malaria, schistosomiasis and other neglected tropical diseases.

Within these collaborations, Merck has provided free access to its proprietary compound library for drug discovery activities to potentially identify new life-changing drugs.


Natalie Mrak

Global Health Strategy & Partnerships Lead, Merck


Kelly Chibale

Neville Isdell Chair in African-centric Drug Discovery and Development, University of Capetown

Benjamin Perry

Senior Discovery Manager, DNDi

Charles Randolph

Head, Global Health, WIPO

Thomas Spangenberg

Head, Global Health Drug Discovery, Merck